[Edaily Reporter Kim Se-yeon ] Hana Card is partnering with Samsung Wallet to launch a debit card that integrates “Travelog,” a service specialized for overseas travel. This collaborative product is aimed at Galaxy users to make overseas payments and currency exchange services even more convenient. (Photo courtesy of Hana Card) Hana Card announced on the 28th that it will launch the “Samsung Wallet Hana Travelog Debit Card,” which integrates Samsung Wallet’s payment functionality. The Samsung Wallet Travelog Card features benefits tailored for overseas travel, including △free currency exchange (100% preferential exchange rate) △waived transaction fees at overseas merchants △waived ATM withdrawal fees abroad. Additionally, it offers a 10% Samsung Wallet Points reward on offline payments made overseas. The Samsung Wallet Travelog Card can be applied for within the Samsung Wallet application (app). To commemorate the launch of this card, Hana Card has partnered with SamsungElectronics(005930)to host an event designed to maximize the Travelog Card payment experience for international travelers. First, from August 1 to December 31, the Samsung Wallet Travelog Card has increased the Samsung Wallet Points earning limit for both domestic and international transactions from 10,000 points to 20,000 points. There is also a prize drawing event. From August 1 to November 30, customers who spend 200,000 won or more at overseas merchants will be eligible to win prizes such as the Galaxy Fold 8, Galaxy Watch 9, Galaxy Buds 4, airline tickets, and keycaps. Seong Young-soo, President of Hana Card, stated, “With the launch of the Samsung Wallet Hana Travelog Check Card, we plan to expand the service base of Travelog and provide greater convenience for overseas payments,” adding, “We intend to continue improving user convenience by reflecting the needs of customers who use our services abroad.”
E-Land World (BBB0) is set to issue up to 40 billion won in public corporate bonds. With investor sentiment toward BBB-rated corporate bonds currently subdued, all eyes are on whether the company can …
(Photo courtesy of MedPacto, Inc.)
MedPacto, Inc.(235980)is adding a medium-dose patient group to the Phase 2 clinical trial of “Vactosertib,” which it is developing as a treatment for osteosarcom…
Medical artificial intelligence (AI) company Coreline Soft Co., Ltd.(384470)announced on the 7th that it has secured a contract for a lung cancer screening project in Lostau, Germany, through Canon Me…